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BK viremia and nephritis are increasing problems in renal
transplant recipients. The exact cause of the increasing
prevalence of this condition remains poorly understood.
Increasing prevalence has been correlated with newer
immunosuppressive agents and the decline in acute rejection
rates in recent years. The clinical manifestation varies from
the asymptomatic state of viremia and nephritis to clinical
renal dysfunction. The diagnosis of this infection is based on
the combination of the presence of urinary decoy cells, virus
in the urine/blood, and typical renal histological findings of
interstitial nephritis. Routine post-transplant screening for BK
viremia and viruria prior to the occurrence of nephritis and
the reduction in immunosuppressive therapy for subjects
with viremia appear to be attractive approaches. The
treatment of BKV nephritis (BKVN) consists of reduction in
immunosuppressive therapy and antiviral therapy with
cidofovir or leflunomide or a combination of both.
Approximately 30–60% of subjects with BKVN experienced
irreversible graft failure. However, in recent years, the
combinations of early detection, prompt diagnosis, and
appropriate reduction in immunosuppressive therapy have
been associated with better outcome. The pathogenesis of
BK virus infection in renal transplant recipients needs to be
explored. The source of BKV infection (donor as opposed to
recipient), the role of host humoral, and cellular immunity to
BKV, and the role of alloimmune activation in renal graft
to the occurrence of nephritis are discussed in this review.
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VIROLOGY
BK virus belongs to the virus family polyomaviridae. Human
polyoma viruses are of two types: JC manifests as viral
encephalopathy and BK as viral nephritis. JC and BK
represent initials of patients in whom they were first detected.
There are other types of polyoma: a murine form that is
known as murine polyoma virus and a simian form that is
known as simian virus (SV)40. Viruses of the family
polyomaviridae contain a 5000 base-pair genome composed
of double-stranded deoxyribonucleic acid (DNA) that
replicates in the host nucleus. Each polyoma virus encodes
three capsid proteins, viral protein (VP)1, VP2, and VP3.
VP1 is the only VP exposed on the outer shell of the virion,
and contains a small groove that interacts with cellular
receptors. BKV is classified into four major sero/genotypes:
group I encodes the prototype strain Dunlop (Dun),
MM, and GS; group II encodes the SB strain; group III
encodes the AS strain; and group IV encodes the MG strains.
The BK viral genome has a region that contains the origin
of replication, transcriptional enhancer regions, and tran-
scriptional promoter regions called the noncoding control
region (NCCR).
HISTORY OF BKV NEPHRITIS
The terminology of BK virus originated from a renal
transplant patient, initial BK, in whom it was first detected
as a clinical disease in 1971.1 There were no reported cases of
this disease for the next 24 years, until Purighalla and co-
workers observed their first case in early 1995.2 Subsequently,
there has been a surge of BKV nephritis (BKVN) cases from
many transplant centers across US, including ours.3–8 The key
factor associated with this increasing incidence remains
unclear. Introduction of immunosuppressive agents such as
mycophenolate mofetil (MMF) and Tacrolimus (Tac) has
been thought to play a causative role in BKVN. However, this
infection is also seen in patients who have never received the
above combinations of immunosuppressive agents, as well as
those receiving sirolimus, and those with steroid avoidance
protocols. Thus, in recent years, the incidence of this
infection has increased in renal transplant recipients and
now poses a threat to improving graft survival.6,7
PREVALENCE OF BKV INFECTION
Approximately 80% of the general population has a
detectable antibody to BKV, which appears early in life and
remains elevated throughout life.9,10 Antibodies to antigen
http://www.kidney-international.org r e v i e w
& 2006 International Society of Nephrology
Received 9 July 2005; accepted 13 September 2005; published online 4
January 2006
Correspondence: S Hariharan, Division of Nephrology, Medical College of
Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, Wisconsin 53226, USA.
E-mail: hari@mcw.edu
Kidney International (2006) 69, 655–662 655
VP1 crossreact with SV40, BKV, and JCV;11 however, a
specific monoclonal antibody can be used to differentiate
various viruses. The prevalence of this virus in the end-stage
renal disease population, kidney donors, and transplant
recipients has not been well defined.
The prevalence of BK viruria, viremia, and nephritis after
renal transplantation has been estimated at 30, 13, and 8%,
respectively.12 The overall prevalence of BKVN at the Medical
College of Wisconsin from 1996 to 2004 is 4.2%, that is, 48
out of 1139 renal transplants. Viremia and viruria are also
seen in liver, heart, and lung transplant recipients, but with a
lower prevalence than in renal transplant recipients.
Although reported, the incidence of clinical native renal
BKVN is rare following other solid organ transplant
recipients such as liver, heart, and lung. Clinical BKVN has
occasionally been seen in immunosuppressed human immuno-
virus patients as well as in individuals with immunodeficiency
syndromes, and rarely in other immunosuppressed individuals
with systemic lupus erythematosus.13,14
CLINICAL FEATURES, DIAGNOSIS, RISK FACTORS, AND
OUTCOME
Clinical features
Most renal transplant recipients with BKVN manifest with
renal dysfunction.4,7,8,15,16 Occasionally, subjects can also
present with ureteric obstruction and hydronephrosis, and
cases of cystitis have been reported.17 In recent years, routine
post-transplant protocol biopsy has also detected BKVN in
the absence of serum creatinine elevation.18,19 Progressive
renal failure has been reported in approximately 30–60% of
cases.7,8,20 Rare fatal disseminated BK virus infection after
cadaveric transplantation has also been reported.21
Diagnosis
The diagnosis of BKV infection is based on the documenta-
tion of viral cytopathic effects (urinary decoy cells), the virus
itself (in blood, urine, and/or renal tissue), immunity to virus
(BKV-specific antibody), and renal histological findings of
nephritis. Each diagnostic modality and its limitations are
shown in Table 1. Urinary decoy cells are a good diagnostic
screening test, but the positive predictive value is around
20%. Thus, demonstration of urinary decoy cells suggests the
presence of BKV in urothelium, but does not confirm BKVN.
Circulating BKV DNA in plasma has been seen in
approximately 10–40% of renal transplant recipients.22,23
However, not all viremic subjects have clinical nephritis.
Demonstration of viremia by blood polymerase chain
reaction (PCR) is a reliable test for nephritis, as it is seen
in nearly 100% of the cases with BKVN. However, the
positive predictive value for nephritis is only 60%. Viruria is
seen in 30–40% of renal transplant recipients and the
quantity is 100-fold over that of blood.6,12,24 Similar to
blood BKV DNA, the utility of urinary BKV DNA has an
excellent negative predictive value, but a poor positive
predictive value; an alternative approach is to amplify viral
VP1 messenger ribonucleic acid (mRNA) in urine, as it may
represent active BKV replication.25 From this single study,
positive and negative predictive values for mRNA in urine are
above 90%; however, this must be confirmed in further
studies. The levels of circulating plasma BKV DNA correlat-
ing with BKVN remain controversial; Hirsch et al.12 reported
copies greater than 7000 with acute BKVN. However, BKVN
can occur even with copies as low as 1000 copies (personal
observation) and better correlation has been noted with
persistent viremia.
The diagnosis of BKVN is usually made by the
demonstration of viral cytopathic effect in renal histology
with inflammatory response. Renal involvement can be focal
in earlier stages and could have predominant fibrotic changes
with minimal inflammatory changes in the later stages of the
disease.26 Nonetheless, histological findings remain the gold
standard diagnostic test (Figure 1) and typical findings are
focal interstitial mononuclear inflammatory cell infiltrates,
presence of plasma cells, necrotic tubular epithelium, and
Table 1 | Diagnosis of BK virus nephritis
Tests Findings Comments
Urine cytology Presence of decoy cells Seen in 40–60% of transplant recipients, good
screening test, positive predictive value around 20%
Viremia (plasma BKV DNA) Copies 47000 per ml of plasma Seen in 10–20% of transplant recipients, good
screening test, positive predictive value around 60%
Viruria (urinary BKV DNA) Copies 100-fold higher than plasma values Seen in 30–40% of transplant recipients, good
screening test, positive predictive value around 40%
Urinary BKV mRNA (active viral
replication)
Copies diagnostic of BKVN To be confirmed in other studies, research tool
BKV DNA in renal tissue Detection of BKV DNA in renal biopsy tissue Negative predictive value 100%, positive predictive
value around 70%
Renal histology Inflammatory changes with viral cytopathic effects,
positive immunoperoxidase reaction with SV40 stain,
predominant CD20-positive lymphocytic infiltrates
Gold standard, invasive procedure, focal lesions,
chronic state with minimal viral cytopathic effects,
mimics acute rejection
Serum BKV-specific antibodies Diagnostic levels of IgM and IgG? Seen in 80–90% of general population
BKV-specific antibodies
and BKV DNA
Diagnostic levels of BKV-specific antibodies IgM, IgG
and BKV DNA?
Research tool
T-cell immunity Diagnostic measurement? Research tool
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presence of homogenous intranuclear inclusion bodies. Renal
interstitial inflammation with BKVN cannot always be
differentiated from acute rejection. Immunohistochemistry
with SV40 staining has been used as an indirect method to
document the presence of BKV in renal tissue. Demonstra-
tion of predominant CD20-positive lymphocytes (B cells) in
renal histology is suggestive of BKV infection.7 The degree of
acuity and chronicity can be differentiated by the degree of
inflammatory response and fibrosis.26
Prior exposure to this virus can be demonstrated by the
presence of BKV-specific immunoglobulin (IgG) antibody in
the circulation. The high prevalence of this infection in the
general population rules out BKV-specific antibody as a
diagnostic test for BKVN.27 The detection of Immunoglo-
bular-M(IgM) and degree of rise of IgM levels remain to be
proven as a diagnostic method for acute BKVN. Recently, we
have evaluated the role of BKV-specific antibody along with
BKV DNA in cases of clinical BKVN.28 Individuals with
BKVN generally have a very high BKV DNA and low BKV-
specific IgG levels. The subjects who recover from BKVN
have undetectable viral copies in circulation with elevated
BKV-specific IgG levels. Combinations of BKV-specific
antibody and BKV DNA are a novel approach to diagnose
as well as manage subjects with BKVN. Deficient humoral
immunity in subjects with viremia and those with BKVN
may be an important factor in the pathogenesis of this
disease. Prompt increase in BKV-specific IgG antibody, with
clearance of viremia and stabilization of renal function, was
noted with reduction in immunosuppression in our series.28
The natural history of BKVN varies from case to case, as
illustrated in Figure 2. Our ability to diagnose BKVN was
delayed owing to misdiagnosis of acute rejection, lack of
knowledge about this disease in the mid-1990s, and
unavailability of diagnostic tools such as BKV DNA and
BKV-specific antibodies. Rapid progression of renal disease
was common, with aggressive treatment for presumptive
acute rejection, as shown by the evaluation of renal failure as
100/serum creatinine (Figure 2a). However, recent cases have
been detected early using appropriate tools such as BKV
DNA and BKV-specific antibodies. Prompt treatment with
reduction in immunosuppression perhaps prevented further
renal injury and arrested progressive renal failure in a case as
shown in Figure 2b.
Risk factors
Investigators have explored various risk factors associated
with the occurrence of BKVN. However, no specific donor,
recipient and transplant variables have been implicated in the
occurrence of this disease. Seronegative subjects who receive
kidneys from seropositive donors appear to have a higher
chance of nephritis in a small pediatric study.29 Deficient
humoral and/or cellular immunity in subjects with BKVN
may lead to a poorer outcome. In our recent analysis,
individual immunosuppressive medications, cold ischemia
time, plasma renin activity (PRA), organ source (living vs
deceased), and human lymphocyte antigen (HLA) mis-
matches did not appear to point out single or multiple risk
factors.30 The level of renal dysfunction, defined as serum
creatinine 42.2 mg/dl at the time of diagnosis of BKVN,
correlated with poorer long-term graft survival.30 In a
recently published series, renal histological features of
moderate to severe fibrosis have been shown to have poorer
outcome.26
Outcome
Approximately 40–60% of renal grafts with BKVN develop
progressive graft loss. We observed lower graft survival in
recipients with BKVN in 2001.7 In 2002, rapid graft failure
was noted when intense treatment with antilymphocyte agent
was implemented as a result of misdiagnosis as acute
rejection.8 Investigators from the University of Maryland
have reported a similar experience.20 As of March 2005, we
have diagnosed a total of 48 cases of BKVN out of 1139
transplants performed from January 1996 to December 2004.
The actuarial renal graft survival of these 48 cases is lower
than the rest of the transplant population, as shown in
Figure 3. Graft failure occurred in 19 of 48 (39%) cases. In
recent years, however, there is a trend toward lower graft loss,
due to the combination of better diagnostic tools, prompt
Figure 1 | Renal histological findings of interstitial infiltrates and
viral cytopathic effects in a case with BKVN.
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Figure 2 | (a) Evolution of renal function using 100/serum
creatinine, illustrating progressive renal failure in a case with
BKVN. (b) Evolution of renal function using 100/serum creatinine,
illustrating stabilization of renal function in a case with BKVN.
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diagnosis, and prompt reduction in immunosuppressive
therapy.
TREATMENT OF BKVN
The management of BKV infection has been aimed at
eliminating the virus, avoiding acute rejection, and preserving
renal function. Potential therapeutic options and limitations
are shown in Table 2. These include reducing immunosup-
pression alone and reducing immunosuppression as well as
antiviral therapy such as cidofovir or leflunomide.31–33
Decreasing the level of immunosuppression in individuals
with BKVN can lead to acute graft rejection. Thus,
prevention of BKVN remains an optimal therapeutic
approach.
Prevention of BKVN by monitoring BK viral loads in renal
transplant patients is an important option, as BKV infection
is diagnosed prior to or at an early stage of nephritis. This
research is in its early stage, as what constitutes a normal,
abnormal, and pathologic elevation in viral load is still being
defined. In a recent analysis, using quantitative real-time
PCR, we have measured the BK viral loads in kidney
transplant patients and have seen that patients who are
PCR-positive in the peripheral blood present with a wide
range of viral loads.23 Pre-emptive reduction of immuno-
suppression alone as a preventive therapy for BKVN appears
to be a safe and attractive option.22,23 In a recent large
prospective study by Brennan et al.,22 pre-emptive reduction
of immunosuppression was successfully performed in
response to BK viremia and BKVN was prevented. Thus,
prevention of nephritis by regular monitoring for viremia/
viruria seems to be a good approach.
Leflunomide is an immunosuppressive agent, yet its
metabolite A77 1726 has antiviral activity in vitro and in
animals. In a recent report, leflunomide was used in 17
subjects with BKVN.33 MMF was discontinued and Tac dose
was decreased with loading dose of leflunomide at 100 mg/
day for 5 days, followed by 20–60 mg daily, with a target
trough blood level of 50–100 mg/ml. Marked reduction in
viremia and viruria occurred in subjects who tolerated
leflunomide, with a target level above 40 mg/ml. However, this
reduction in viremia and viruria may be secondary to
discontinuation of MMF and dose reduction of Tac.
Cidofovir has been used in the treatment of BKVN in an
uncontrolled fashion.31,32 However, as it is nephrotoxic, it is
primarily excreted by the kidneys and adequate hydration is
required. The use of other antiviral agents such as amantidine
has been attempted unsuccessfully.34 Vidarabine has been
used in bone marrow recipients with cystitis35 and gamma-
globulin has been attempted to augment the immune
response.
Our recent analysis of 25 cases with BKVN shows
successful stabilization of renal function with reduction in
immunosuppression alone.30 Quantification of this evolution
showed a loss of creatinine clearance of 4.8 ml/min/month
for a period of 4 months prior to the diagnosis of BKVN, and
a loss of 0.7 ml/min/month during subsequent follow-up.
Reducing immunosuppression alone was successful and
appears to be a safe and noncontroversial approach in 16
out of 25 cases, as documented by stabilization of renal
function and clearance of viremia.30
Modifying immunosuppression for subjects with BKVN,
avoiding further renal injury, and delaying the progression of
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Figure 3 | Lower actuarial graft survival rates in patients with
BKVN – results from the Medical College of Wisconsin 1996–2004.
Table 2 | Treatment of BKV nephritis
Mode of action Comments
Amantindine Antiviral Poor efficacy?
Vidarabine Antiviral Used in cystitis, efficacy in nephritis unknown
Cidofovir Antiviral Nephrotoxicity, potential benefit with
reduction in immunosuppression, however,
needs evaluation
Leflunomide Antiviral Potential clinical efficacy with therapeutic
trough level (50–100mg/ml) with reduction in
immunosuppression
FK 778 Antiviral Shorter-acting leflunomide, investigational
agent, and efficacy unknown
Gammaglobulin Augments immunity Efficacy unknown
Reduction, discontinuation, and/or change in
immunosuppressive agents (MMF, Tac, CSA,
sirolimus, prednisone)
Decreasing immunosuppression Safe and appears effective, risk of acute
rejection in selected recipients
Prevention: monitoring viral disease (urinary
decoy cells, viremia, viruria, and surveillance
biopsy) and altering immunosuppression
Diagnosis of preclinical, subclinical,
or early nephritis
Safe and effective with proper monitoring, risk
of acute rejection with immunosuppressive
alterations
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renal failure remain the main focus of therapy. Measuring
circulating virological and immune markers such as BKV
DNA copies and levels of BKV-specific IgG antibodies should
be used as a tool in managing BKVN. Measuring time to
disappearance of BKV DNA from circulation, documentation
of increase in BKV-specific IgG antibody level, and stabiliza-
tion of renal function with the appropriate therapy should be
used for defining treatment of BKVN.28
Repeat transplantation has been successfully performed on
subjects with graft failure due to BKVN.36 A pooled analysis
from five US transplant centers revealed that successful
transplantation can be performed without recurrence in nine
out of 10 cases, with a mean follow-up of over 2 years.36
These subjects were virologically quiescent prior to their
second transplant and their immunosuppression varied from
center to center and from case to case. Thus, the risk of
recurrent BKVN after second transplantation is low but real
and should not be ignored.
PATHOGENESIS OF BKV NEPHRITIS
The exact pathogenesis of BKV infection leading to BKVN
remains unclear. The hypothetical mechanisms involved are
shown in Figure 4 and are as follows: source of BKV;
immunological aspects such as host humoral and cellular
immunity, alloimmune activation and immunosuppression
medications; renal specificity such as tropism and ischemic
injury; and viral virulence.
Source
There are two competing hypotheses regarding the source of
BKV infection. The first hypothesis is that transmission
occurs through the donor kidney.27 In such a case, the
transmission may occur directly through the transplanted
organ in recipients who have never been exposed to BKV. In a
recent pediatric transplant study with BKVN, the source of
infection was thought to be derived from the donor, as many
recipients were never exposed to this infection prior to
transplantation.29 However, the majority of adult renal
transplant recipients have been exposed to this infection
prior to transplantation. The second hypothesis is that latent
BKV infection is reactivated in the renal epithelium after
transplantation. Since BKV resides in the renal epithelium, its
reactivation may be due to defective immune surveillance in
the immunosuppressed recipient and manifests as nephri-
tis.3,5,24,37 Occurrence of BKVN has also been noted in
recipients who have had pre-transplant bilateral native
nephrectomy (personal observation). Thus, it is possible that
the viral latency may be located in ureteral and bladder
mucosa and not renal per se, and may reactivate after
transplantation.
In a recent retrospective analysis, pretransplant donor and
recipient BKV-specific antibody correlated to the occurrence
of post-transplant infection.38 Donor antibody titer corre-
lated inversely to the onset of post-transplant viruria
(P¼ 0.001) and directly proportional to duration of viruria
(P¼ 0.014) and peak urine viral titers (P¼ 0.005). Thus, the
source of infection form the donor may explain the early
onset of infection; however, reactivation of virus in the
recipient’s urothelium is still a potential pathogenetic
mechanism involved in this infection. Uncovering the modes
of BKV infection, that is, exogenous vs reactivation, is of
significance in understanding the disease process.
Immunology
To date, the intensity of immunosuppression has been
implicated in causing BKVN with minimal attention to the
host immunity. From other viral infections, it is clear that
natural killer cells of the immune system offer antiviral
cytotoxic activity. Adaptive immune responses follow with
CD8-positive cytotoxic T cells. CD4-positive T cells boost
antibody production with macrophage and augment viral
clearance. Thus, host humoral and cellular immunity may
play a major role in the pathogenesis of BKVN.
Humoral immunity
A fatal case of BKV infection with hyper-IgM immunodefi-
ciency may suggest a mechanism for humoral antibody
protection against BKV.13 Lack of development of BKV-
specific IgG may be the key feature in the manifestation of
this disease. IgG class switching is impaired in hyper-IgM
immunodeficiency by lack of function of the CD40 ligand.
Similar class switching may be defective in renal transplant
recipients due to immunomodulatory drugs. Humoral anti-
body testing was carried out in renal transplant recipients in
the early 1980s when this disease was not clinically
significant,27 as well as recently in a small pediatric study.29
Recipients with prior immunity to BKV and circulating
viral copies may not develop nephritis, as opposed to those
with deficient humoral immunity. Thus, a patient with an
elevated viral load with a robust level of humoral antibody
may not require any intervention at all, whereas a patient
with a small elevation in viral load and no detectable anti-
BKV immunity may be in grave danger. At the Medical College
of Wisconsin, we have evaluated 20 renal transplant recipients
at various stages of BKVN.28 The mean BKV-specific IgG
Source of BK  virus,
donor vs recipient
BK virus virulence,
molecular type
BK viremia
BKV nephritis
Rental tubular
cell tropism
Host cellular and
humoral immunity
Immunosuppressive
agent
CD40 ligand
Renal ischemic 
injury
Alloimmune
activation
Figure 4 | Potential pathogenetic mechanisms involved in the
occurrence of BKVN from BK viremia. These include sources of BKV
infection, molecular viral type, renal tropism, host immunity, and
renal transplant ischemic injury prior to engraftment, alloimmune
activation, immunosuppression type, and defect in CD40 ligand.
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levels in patients at the time of diagnosis of BKVN and those
with stabilizing BKVN after reduction of immunosuppres-
sion were 64 and 39 enzyme immune assay (EIA) units, and
they were significantly lower than the levels of 138 EIA units
seen in patients with resolved BKVN, P¼ 0.007 and 0.008.28
The mean BKV-specific IgM level in patients with stabilizing
BKVN was 130 EIA units, which was higher than the levels of
51 EIA units detected in patients with resolved BKVN;
P¼ 0.006. The means and ranges of plasma BKV loads for
subjects at the time of diagnosis, during stabilization, and
those who had resolved BKVN were 955 925
(21 153–2 999 632), 5642 (593–14 636), and 42 (0–243)
copies/ml of plasma, respectively. From our series, after a
complete resolution of nephritis with stabilization of renal
function, BKV-specific IgG antibody increased in all subjects
from their baseline BKV-specific IgG antibody level. From
our study, we also observed that there was a trend toward
rapid clearance of viremia in subjects with BKV IgG450 EIA
units compared to those who had IgG
o50 EIA units.28 Thus, humoral immunity may play an
important role in the pathogenesis of BKVN. Deficient
humoral immunity at the time of transplant and BKV
infection may determine the occurrence of BKVN and its
subsequent outcome.
Cellular immunity
Subjects with elevated BKV-specific IgG can still develop
BKVN, suggesting the possible role of defective cellular
immunity. The effector function of T lymphocytes is critical
to viral immunity. It is conceivable that a lack of cellular
immune response to a rising viral load determines the
occurrence of BKVN. Investigators from Italy have identified
defective cellular immunity using Enzyme-Linked Immuno
SPOT (ELISPOT) signal in subjects with BKVN.39 The
absence of ELISPOT signal was noted at the time of diagnosis
of BKVN in two cases, and this reversed with reduction in
immunosuppressive therapy. Establishing a relationship
between defective T-cell response and BKV infection may
be of great clinical significance and needs further investi-
gation.
Alloimmune activation
Occurrence of BKVN in renal transplant recipients, as
opposed to heart and liver transplant subjects, unveils the
role of alloimmune activation with BKV activation and
subsequent frank nephritis. Investigators from Emory Uni-
versity have explored the role of immune activation in a
mouse transplant model, and have documented that viral
nephritis occurs only in the presence of alloimmune
activation.40 Thus, subclinical alloimmune activation in renal
graft may trigger BKV replication and nephritis. This also
explains why this infection occurs in renal grafts only, as
opposed to other solid organ transplant recipients. However,
alloimmune activation is usually a result of suboptimal
immunosuppression that contradicts BKVN therapy, which is
a reduction in immunosuppressive therapy.
Immunosuppressive medications
Immunosuppressive combination therapies have been im-
plicated in the occurrence of BKVN. Prior to 1995, BKVN
was rarely identified as a problem in renal transplant
recipients. Around this period, MMF and Tac were
introduced as immunosuppressive agents for clinical trans-
plantation. Prompt reduction in acute rejection rates with
potent immunosuppressive agents has been accompanied by
an increasing incidence of BKVN. However, BKVN has also
been seen occasionally in recipients receiving cyclosporine
(CsA) and sirolimus.41 Hence, the occurrence of BKVN is not
due to specific immunosuppressive agents, but may be
related to the overall degree of immunosuppression. Brennan
et al.22 prospectively evaluated the differences between
viremia and viruria with three immunosuppressive combina-
tion therapies. Viruria was the highest with Tac-MMF
combination (46%) compared to CsA-MMF (13%) therapy,
and choice of calcineurin inhibitor or adjuvant immunosup-
pression did not influence viremia or nephritis. The role of
induction antibody and steroid avoidance therapies in
influencing BK viremia and nephritis requires further
clarification.
Renal specificity
BKV, which infects renal tubular cells, is most commonly
seen in renal transplant recipients, as opposed to other
immunosuppressed individuals and other solid organ
transplant recipients.
Renal tubular cells
The precise sites of activation of BKV and mechanisms
through which BKV infects renal tubular epithelial cells in
transplant recipients are unknown. In animal models, viral
replication during the acute phase of infection is seen in
pulmonary, systemic vascular endothelial cells, and in
spleenic lymphoid cells. However, viral nucleic acids are seen
in renal tubular epithelial cells at 2 months and the virus itself
after 6 months, which remains the major site of viral
persistence.42 Thus, BKV has tropism to renal tubular
epithelial cells and replication occurs in these cells. The
receptor site at the cellular level remains to be identified.
Renal ischemic injury
BKV can be detected in the urine of renal transplant
recipients; however, it can be present in other renal diseases
as well as in the urine of normal healthy individuals.43
Approximately 40% of renal transplant patients shed virus in
the urine.12 It is still unclear why this infection occurs
predominantly in renal transplants and not in immunosup-
pressed heart and liver transplant recipients. It is conceivable
that renal ischemic injury during organ retrieval and
implantation occurs only in kidney transplant compared to
heart or liver transplant. Thus, ischemic injury at the time of
transplantation may play a role in creating an environment
for viral replication leading to nephritis. However, there is no
correlation between cold ischemia time and organ source
660 Kidney International (2006) 69, 655–662
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(deceased vs living) and the occurrence of BKVN. In
addition, occurrence of nephritis around a year after
transplantation challenges the role of ischemic injury as an
important causative factor in nephritis.
BKV virulence
BKV genomic heterogeneity has been described in systemic
lupus erythematosus and bone marrow transplant recipients,
as well as in healthy donors.44,45 The reported rates of
mutation differ in these reports and may be correlated with
changes in disease status.44,46 It is plausible that specific
BKV types may have altered virulence, or changing
genomic sequence may be associated with the occurrence of
nephritis or a more severe form of the disease. The NCCR
shows a high degree of sequence variability. In the report,
Rhandawa et al. sequenced the NCCR in 26 paraffin-
embedded biopsies from 15 patients with BKV nephritis
and compared them to the archetype WW strain.47 Their
results demonstrated that there is an extensive natural
variation in the viral sequence between patients. However,
an analysis on NCCR sequence variations did not reveal any
rearrangement pattern in five subjects with nephritis.48 Thus,
the role of molecular characterization at the DNA sequence
level still needs to be explored.
Thus, the pathogenesis of BKVN is complex, as the virus
may be introduced into the recipient through the donor, or
reactivation in the recipient, or both. Tropism of this virus for
renal tubular cells lays the foundation for the infection, which
may be modified by host humoral and cellular immunity, as
well as recipients’ alloimmune activation in the graft, with
concomitant immunosuppressive therapy leading to nephritis.
CONCLUSION
BKVN is an important problem after renal transplantation
that has limited improvements in graft survival. Increasing
awareness of this condition, utility of BKV DNA estimation
in blood and urine, careful renal histological evaluation, and
avoiding further aggressive immunosuppression after the
diagnosis of BKVN are changing the outcome of this disease.
Screening for BKV in blood and urine, along with pre-
emptive reduction in immunosuppression, has been a useful
strategy to prevent BKVN. The role of BKV-specific antibody
and host cellular immunity in the pathogenesis of BKVN is
evolving. Alloimmune activation, as a potential factor
influencing the occurrence of BKVN, remains strong in renal
transplant recipients; however, our ability to measure
alloimmune activation remains a challenge. Virological
variance such as molecular type of virus and changing
virulence by altering DNA sequence needs further studies.
Reducing immunosuppression appears to be the best
approach for the treatment of BKVN until a safe antiviral
agent becomes available to treat this condition.
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